Arbutus Biopharma Corp (ABUS)

Schlusskurs vom Vortag:

$2.68

Offen:

$2.71

24-Stunden-Volumen:

678.62K

Marktkapitalisierung:

$488.27M

Einnahmen:

$18.14M

Nettoeinkommen (Verlust:

$-72.85M

KGV:

-5.8913

EPS:

-0.46

Netto-Cashflow:

$-86.94M

1W Leistung:

-0.73%

1M Leistung:

-7.19%

6M Leistung:

+41.15%

1J Leistung:

+7.97%

1-Tages-Spanne:

$2.70

$2.85

52-Wochen-Spanne:

$1.69

$3.29

Arbutus Biopharma Corp Stock (ABUS) Company Profile

Firmenname

Arbutus Biopharma Corp

Sektor

Healthcare (1213)

Branche

Biotechnology (699)

Telefon

604-419-3200

Adresse

100-8900 Glenlyon Parkway, Burnaby, PA

Mitarbeiter

130

Twitter

@arbutusbio

Nächster Verdiensttermin

2024-05-22

Neueste SEC-Einreichungen

ABUS's Discussions on Twitter

Arbutus Biopharma Corp Stock (ABUS) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2022-02-02	Hochstufung	Jefferies	Hold → Buy
2021-02-25	Eingeleitet	Jefferies	Hold
2020-12-17	Eingeleitet	H.C. Wainwright	Buy
2020-07-27	Fortgesetzt	JMP Securities	Mkt Outperform
2020-07-24	Herabstufung	Robert W. Baird	Outperform → Neutral
2020-05-19	Hochstufung	Wedbush	Neutral → Outperform
2020-03-06	Hochstufung	Chardan Capital Markets	Neutral → Buy
2020-02-20	Eingeleitet	Robert W. Baird	Outperform
2020-02-05	Hochstufung	JMP Securities	Mkt Perform → Mkt Outperform
2019-10-07	Bestätigt	B. Riley FBR	Buy
2019-10-04	Herabstufung	Chardan Capital Markets	Buy → Neutral
2018-10-16	Hochstufung	B. Riley FBR	Neutral → Buy
2018-10-15	Hochstufung	Wedbush	Underperform → Neutral
2018-10-12	Bestätigt	Chardan Capital Markets	Buy
2018-07-06	Herabstufung	B. Riley FBR, Inc.	Buy → Neutral
2018-03-19	Fortgesetzt	Chardan Capital Markets	Buy
2018-03-19	Herabstufung	Wedbush	Outperform → Neutral
2018-01-05	Eingeleitet	B. Riley FBR, Inc.	Buy
2017-04-04	Hochstufung	Chardan Capital Markets	Neutral → Buy
2017-02-01	Bestätigt	Wedbush	Outperform
2016-12-13	Herabstufung	Chardan Capital Markets	Buy → Neutral
2016-11-30	Hochstufung	Chardan Capital Markets	Neutral → Buy

Alle ansehen

Arbutus Biopharma Corp Aktie (ABUS) Neueste Nachrichten

Arbutus Biopharma (ABUS) Reports Q1 Loss, Misses Revenue Estimates

Zacks Investment Research

Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024

GlobeNewswire Inc.

Are Medical Stocks Lagging Arbutus Biopharma (ABUS) This Year?

Zacks Investment Research

Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update

GlobeNewswire Inc.

Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna

GlobeNewswire Inc.

Arbutus to Participate in Two Upcoming Investor Conferences

GlobeNewswire Inc.

Finanzdaten der Arbutus Biopharma Corp-Aktie (ABUS)

Arbutus Biopharma Corp (ABUS) Umsatz 2024

Arbutus Biopharma Corp (ABUS) Nettogewinn 2024

Arbutus Biopharma Corp (ABUS) Free Cashflow 2024

Arbutus Biopharma Corp (ABUS) Gewinn je Aktie 2024